Consistently, JMJD3 deficiency was reported to promote malignant progression of human pancreatic carcinoma by decreasing the expression of C/EBPα [40], a potential inhibitory partner of E2F1. This evidence concerns the gene E2F1 and exocrine pancreatic carcinoma.